catalent to buy juniper pharmaceuticals for 128m
- الجميع
Catalent Signs Agreement to Acquire Juniper …
2018年7月3日· SOMERSET, N.J., July 3, 2018 – Catalent, Inc. (NYSE: CTLT), the leading …
Catalent to acquire Boston's Juniper Pharmaceuticals for $128M
2018年7月3日· Drug contract manufacturer Catalent has agreed to acquire Boston-based …
Recon: Catalent to Buy Juniper Pharmaceuticals for $128m
2018年7月3日· Catalent to buy Juniper Pharmaceuticals for $11.50 per share () () Novartis …
Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc.
2018年7月3日· $133 Million Deal Adds European Early Development Center of Excellence to …
Catalent to acquire Juniper Pharmaceuticals
2018年7月3日· Catalent, Inc, a leading global provider of advanced delivery technologies and …
Catalent to buy specialty healthcare firm Juniper Pharmaceuticals
Catalent to buy speciality healthcare firm Juniper Pharmaceuticals US-based drug delivery …
Catalent to Acquire Juniper Pharmaceuticals
2018年7月3日· Catalent’s acquisition of Juniper Pharmaceuticals further expands its early …
Catalent completes $130M acquisition of Juniper
Dive Brief: Catalent announced Tuesday that it completed its deal to acquire U.K.-based …
Catalent to buy Juniper Pharmaceuticals for $11.50 per share
2018年7月3日· 2 Min Read. (Reuters) - U.S. drug contract manufacturer Catalent Inc CTLT.N …
Catalent Completes $133-Million Acquisition of Juniper …
2018年8月16日· Earlier this year (2018), Catalent announced that it would invest in its …
Catalent to acquire Juniper Pharmaceuticals – Life Sciences …
Catalent Inc, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has agreed to acquire Juniper Pharmaceuticals, including its Nottingham, UK-based Juniper Pharma Services division. When combined with Catalent’s existing industry ...
Catalent to acquire Juniper Pharmaceuticals
2018年7月3日· Catalent, Inc, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has announced that it is acquiring Juniper Pharmaceuticals, including its Nottingham, UK-based Juniper Pharma Services division. When combined with Catalent’s existing …
Catalent to buy specialty healthcare firm Juniper Pharmaceuticals
Catalent to buy speciality healthcare firm Juniper Pharmaceuticals US-based drug delivery technology company Catalent has agreed to purchase all outstanding shares of specialty healthcare firm Juniper Pharmaceuticals for a total cash consideration of $139.6m, which represents $11.50 per share.
Catalent Signs Agreement to Acquire Juniper Pharmaceuticals
2018年7月3日· The Acquisition. Under its acquisition agreement with Juniper, a subsidiary of Catalent will promptly commence a tender offer to purchase all of Juniper’s shares for a price of $11.50, net to the seller in cash. Following the conclusion of the tender offer, Catalent intends to complete the transaction by acquiring the remainder of the Juniper ...
Juniper Inks Deal to be Acquired by Catalent, Shares Up
2018年7月4日· Juniper Pharmaceuticals, Inc. (JNP) inks a deal with Catalent, Inc. Per the deal, Catalent will acquire all of the outstanding shares of Juniper at a price of $11.50 per share in cash.
Catalent, Inc - Catalent Completes Tender Offer for All Outstanding Shares of Juniper Pharmaceuticals…
2018年8月14日· SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE:CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the successful completion of the previously announced tender offer by Catalent Boston, Inc. …
Catalent To Acquire Juniper Pharmaceuticals in $133-Million Deal
2018年7月10日· Catalent has agreed to acquire Juniper Pharmaceuticals, a Boston, Massachusetts-headquartered specialty pharmaceutical company with contract development and manufacturing services, including its Nottingham, UK-based Juniper Pharma Services Division, in a deal worth $133 million. The acquisition of Juniper would …
Catalent to Acquire Juniper, Adding Early Drug Development Capabilities
2018年7月3日· Catalent said today it has agreed to acquire Juniper Pharmaceuticals for $133 million, in a deal that adds a U.K. center of excellence for early drug development to similar centers that the buyer ...
Wired News - Catalent Acquires Juniper Pharma - Yahoo!
2018年7月6日· LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want access to our free research report on Catalent, Inc. (NYSE: CTLT), all you need to do is sign up now by clicking the following link www.active ...
Juniper Pharmaceuticals Signs Definitive …
2018年7月3日· BOSTON, July 3, 2018 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), a diversified healthcare company with core businesses of its CRINONE ® (progesterone gel) franchise and …
Catalent to acquire Juniper Pharmaceuticals – Life Sciences …
Catalent Inc, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has agreed to acquire Juniper Pharmaceuticals, including its Nottingham, UK-based Juniper Pharma Services division. When combined with Catalent’s existing industry ...
Catalent to acquire Boston's Juniper Pharmaceuticals for $128M …
2018年7月6日· Juniper provides drug development and manufacturing services to other biotech and pharmaceutical companies, and also generates revenue by supplying Merck KGaA with an infertility treatment.
Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc.
2018年7月3日· Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has agreed to acquire Juniper Pharmaceuticals, Inc. (NASDAQ: JNPR), including its Nottingham, U.K.-based Juniper Pharma Services division.
Juniper Inks Deal to be Acquired by Catalent, Shares Up
2018年7月4日· Juniper Pharmaceuticals, Inc. (JNP) inks a deal with Catalent, Inc. Per the deal, Catalent will acquire all of the outstanding shares of Juniper at a price of $11.50 per share in cash.
Catalent Signs Agreement to Acquire Juniper Pharmaceuticals
2018年7月3日· The Acquisition. Under its acquisition agreement with Juniper, a subsidiary of Catalent will promptly commence a tender offer to purchase all of Juniper’s shares for a price of $11.50, net to the seller in cash. Following the conclusion of the tender offer, Catalent intends to complete the transaction by acquiring the remainder of the Juniper ...
Catalent acquires Juniper Pharmaceuticals
2018年8月16日· Catalent is a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The acquisition of Juniper expands and strengthens Catalent’s offerings in formulation development, bioavailability solutions and clinical-scale oral dose manufacturing.
Catalent agrees to buy Juniper Pharmaceuticals - Cleanroom …
2018年7月4日· Catalent, the US-based drug development specialist, has agreed to acquire Boston-based Juniper Pharmaceuticals, including its Pharma Services division located in Nottingham in the UK. The acquisition of Juniper will …
Catalent : CORRECTING and REPLACING Catalent Signs Agreement to Acquire Juniper Pharmaceuticals…
2018年7月3日· $133 Million Deal Adds European Early Development Center of Excellence to Global Network ... | August 4, 2022
CORRECTING and REPLACING Catalent Signs Agreement to Acquire Juniper Pharmaceuticals…
2018年7月8日· SOMERSET, N.J.--(BUSINESS WIRE)--Jul 8, 2018--Reissuing release dated July 03, 2018 to correct Juniper Pharmaceuticals, Inc. ticker symbol in first sentence of first paragraph. The corrected release reads: …
Catalent acquires Juniper Pharmaceuticals for $133m
2018年7月3日· Earlier this year, Catalent announced plans to invest in its Somerset, NJ facility to create an additional center of excellence on America’s East Coast. The company also completed a $5.5m expansion program at its 200,000+ square foot facility in Philadelphia, PA in April of this year.
Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc.
2018年7月3日· $133 Million Deal Adds European Early Development Center of Excellence to Global Network Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has agreed to acquire Juniper Pharmaceuticals, Inc. (NASDAQ: JNP), …
Catalent to acquire Boston's Juniper Pharmaceuticals for $128M …
2018年7月6日· Juniper provides drug development and manufacturing services to other biotech and pharmaceutical companies, and also generates revenue by supplying Merck KGaA with an infertility treatment.
Juniper Inks Deal to be Acquired by Catalent, Shares Up
2018年7月4日· Juniper Pharmaceuticals, Inc. (JNP) inks a deal with Catalent, Inc. Per the deal, Catalent will acquire all of the outstanding shares of Juniper at a price of $11.50 per share in cash.
Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc.
The Acquisition. Under its acquisition agreement with Juniper, a subsidiary of Catalent will promptly commence a tender offer to purchase all of Juniper’s shares for a price of $11.50, net to the seller in cash. Following the conclusion of the tender offer, Catalent intends to complete the transaction by acquiring the remainder of the Juniper ...
Catalent completes $130M acquisition of Juniper | BioPharma Dive
Dive Brief: Catalent announced Tuesday that it completed its deal to acquire U.K.-based Juniper Pharmaceuticals for $11.50 per share, or a total value of $130 million. The acquisition will strengthen Catalent’s offerings in formulation development, bioavailability solutions, and clinical-scale oral dose manufacturing.
Catalent to Acquire Juniper, Adding Early Drug Development Capabilities
2018年7月3日· Catalent said today it has agreed to acquire Juniper Pharmaceuticals for $133 million, in a deal that adds a U.K. center of excellence for early drug development to similar centers that the buyer ...
CORRECTING and REPLACING Catalent Signs Agreement to Acquire Juniper Pharmaceuticals…
2018年7月8日· SOMERSET, N.J.--(BUSINESS WIRE)--Jul 8, 2018--Reissuing release dated July 03, 2018 to correct Juniper Pharmaceuticals, Inc. ticker symbol in first sentence of first paragraph. The corrected release reads: AP NEWS Email: Go Listen Sections U.S. News ...
Catalent, Inc - Catalent Completes Tender Offer for All Outstanding Shares of Juniper Pharmaceuticals…
2018年8月14日· Catalent, Inc. (NYSE:CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the successful completion of the previously announced tender offer by Catalent Boston, Inc. (“Merger Sub”), a subsidiary of Catalent Pharma Solutions, Inc. …
Catalent inks $133M deal to buy Juniper Pharmaceuticals, …
2018年7月3日· The buy out — at $11.50 a share — brings 150 staffers and their Ju niper Phar ma Ser vices di vi sion in Not ting ham. Catal ent is look ing to add their ex per tise on for mu la tion de vel ...
Catalent to Acquire RheinCell Therapeutics
2021年6月24日· SOMERSET, N.J. – June 24, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has reached an agreement to acquire RheinCell Therapeutics GmbH, a developer and manufacturer ...
Next: flame tree group holdings limited